These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C. Niu X; Zhang T; Liao L; Zhou L; Lindner DJ; Zhou M; Rini B; Yan Q; Yang H Oncogene; 2012 Feb; 31(6):776-86. PubMed ID: 21725364 [TBL] [Abstract][Full Text] [Related]
4. pVHL/HIF-regulated CD70 expression is associated with infiltration of CD27+ lymphocytes and increased serum levels of soluble CD27 in clear cell renal cell carcinoma. Ruf M; Mittmann C; Nowicka AM; Hartmann A; Hermanns T; Poyet C; van den Broek M; Sulser T; Moch H; Schraml P Clin Cancer Res; 2015 Feb; 21(4):889-98. PubMed ID: 25691774 [TBL] [Abstract][Full Text] [Related]
5. Prolyl Hydroxylase 3 Knockdown Accelerates Zacharias NM; Wang L; Maity T; Li L; Millward SW; Karam JA; Wood CG; Navai N Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799686 [TBL] [Abstract][Full Text] [Related]
6. Junction plakoglobin regulates and destabilizes HIF2α to inhibit tumorigenesis of renal cell carcinoma. Chen K; Zeng J; Sun Y; Ouyang W; Yu G; Zhou H; Zhang Y; Yao W; Xiao W; Hu J; Xing J; Xiao K; Wu L; Chen Z; Ye Z; Xu H Cancer Commun (Lond); 2021 Apr; 41(4):316-332. PubMed ID: 33591636 [TBL] [Abstract][Full Text] [Related]
7. Restricted expression of miR-30c-2-3p and miR-30a-3p in clear cell renal cell carcinomas enhances HIF2α activity. Mathew LK; Lee SS; Skuli N; Rao S; Keith B; Nathanson KL; Lal P; Simon MC Cancer Discov; 2014 Jan; 4(1):53-60. PubMed ID: 24189146 [TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear‑cell renal cell carcinoma treated with sunitinib as first‑line treatment. Wierzbicki PM; Klacz J; Kotulak-Chrzaszcz A; Wronska A; Stanislawowski M; Rybarczyk A; Ludziejewska A; Kmiec Z; Matuszewski M Int J Oncol; 2019 Aug; 55(2):371-390. PubMed ID: 31268155 [TBL] [Abstract][Full Text] [Related]
9. Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma. Luu VD; Boysen G; Struckmann K; Casagrande S; von Teichman A; Wild PJ; Sulser T; Schraml P; Moch H Clin Cancer Res; 2009 May; 15(10):3297-304. PubMed ID: 19401348 [TBL] [Abstract][Full Text] [Related]
10. Formation of Renal Cysts and Tumors in Vhl/Trp53-Deficient Mice Requires HIF1α and HIF2α. Schönenberger D; Harlander S; Rajski M; Jacobs RA; Lundby AK; Adlesic M; Hejhal T; Wild PJ; Lundby C; Frew IJ Cancer Res; 2016 Apr; 76(7):2025-36. PubMed ID: 26759234 [TBL] [Abstract][Full Text] [Related]
11. Suppressive effects of iron chelation in clear cell renal cell carcinoma and their dependency on VHL inactivation. Greene CJ; Sharma NJ; Fiorica PN; Forrester E; Smith GJ; Gross KW; Kauffman EC Free Radic Biol Med; 2019 Mar; 133():295-309. PubMed ID: 30553971 [TBL] [Abstract][Full Text] [Related]
12. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition. Chintala S; Najrana T; Toth K; Cao S; Durrani FA; Pili R; Rustum YM BMC Cancer; 2012 Jul; 12():293. PubMed ID: 22804960 [TBL] [Abstract][Full Text] [Related]
13. USP7 depletion potentiates HIF2α degradation and inhibits clear cell renal cell carcinoma progression. Tu R; Ma J; Chen Y; Kang Y; Ren D; Cai Z; Zhang R; Pan Y; Liu Y; Da Y; Xu Y; Yu Y; Wang D; Wang J; Dong Y; Lu X; Zhang C Cell Death Dis; 2024 Oct; 15(10):749. PubMed ID: 39406703 [TBL] [Abstract][Full Text] [Related]
14. Suppression of renal cell carcinoma growth by inhibition of Notch signaling in vitro and in vivo. Sjölund J; Johansson M; Manna S; Norin C; Pietras A; Beckman S; Nilsson E; Ljungberg B; Axelson H J Clin Invest; 2008 Jan; 118(1):217-28. PubMed ID: 18079963 [TBL] [Abstract][Full Text] [Related]
15. Autophagy mediates HIF2α degradation and suppresses renal tumorigenesis. Liu XD; Yao J; Tripathi DN; Ding Z; Xu Y; Sun M; Zhang J; Bai S; German P; Hoang A; Zhou L; Jonasch D; Zhang X; Conti CJ; Efstathiou E; Tannir NM; Eissa NT; Mills GB; Walker CL; Jonasch E Oncogene; 2015 May; 34(19):2450-60. PubMed ID: 24998849 [TBL] [Abstract][Full Text] [Related]
16. Evolution of the HIF targeted therapy in clear cell renal cell carcinoma. Golijanin B; Malshy K; Khaleel S; Lagos G; Amin A; Cheng L; Golijanin D; Mega A Cancer Treat Rev; 2023 Dec; 121():102645. PubMed ID: 37879247 [TBL] [Abstract][Full Text] [Related]
17. Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma. Kucejova B; Peña-Llopis S; Yamasaki T; Sivanand S; Tran TA; Alexander S; Wolff NC; Lotan Y; Xie XJ; Kabbani W; Kapur P; Brugarolas J Mol Cancer Res; 2011 Sep; 9(9):1255-65. PubMed ID: 21798997 [TBL] [Abstract][Full Text] [Related]
18. BAP1 maintains HIF-dependent interferon beta induction to suppress tumor growth in clear cell renal cell carcinoma. Langbein LE; El Hajjar R; He S; Sementino E; Zhong Z; Jiang W; Leiby BE; Li L; Uzzo RG; Testa JR; Yang H Cancer Lett; 2022 Oct; 547():215885. PubMed ID: 35995140 [TBL] [Abstract][Full Text] [Related]
19. MicroRNA-185 inhibits cell proliferation and induces cell apoptosis by targeting VEGFA directly in von Hippel-Lindau-inactivated clear cell renal cell carcinoma. Ma X; Shen D; Li H; Zhang Y; Lv X; Huang Q; Gao Y; Li X; Gu L; Xiu S; Bao X; Duan J; Zhang X Urol Oncol; 2015 Apr; 33(4):169.e1-11. PubMed ID: 25700976 [TBL] [Abstract][Full Text] [Related]
20. miR-30c-2-3p and miR-30a-3p: new pieces of the jigsaw puzzle in HIF2α regulation. Moch H; Lukamowicz-Rajska M Cancer Discov; 2014 Jan; 4(1):22-4. PubMed ID: 24402943 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]